TY - JOUR
T1 - Stem cell therapy for cerebral palsy
AU - Bartley, John
AU - Carroll, James E.
N1 - Funding Information:
Supported in part by NIH grant NS43439-01 and the Research Administration of the Veterans Administration Hospital, Augusta, GA, USA.
PY - 2003/7
Y1 - 2003/7
N2 - Cerebral palsy is a group of brain diseases which produce chronic motor disability in children. The causes are quite varied and range from abnormalities of brain development to birth-related injuries to postnatal brain injuries. Due to the increased survival of very premature infants, the incidence of cerebral palsy may be increasing. While premature infants and term infants who have suffered neonatal hypoxic-ischaemic (HI) injury represent only a minority of the total cerebral palsy population, this group demonstrates easily identifiable clinical findings, and much of their injury is to oligodendrocytes and the cerebral white matter. While the use of stem cell therapy is promising, there are no controlled trials in humans with cerebral palsy and only a few trials in patients with other neurologic disorders. However, studies in animals with experimentally induced strokes or traumatic injuries have indicated that benefit is possible. The potential to do these transplants via injection into the vasculature rather than directly into the brain increases the likelihood of timely human studies. As a result, variables appropriate to human experiments with intravascular injection of cells, such as cell type, timing of the transplant and effect on function, need to be systematically performed in animal models with HI injury, with the hope of rapidly translating these experiments to human trials.
AB - Cerebral palsy is a group of brain diseases which produce chronic motor disability in children. The causes are quite varied and range from abnormalities of brain development to birth-related injuries to postnatal brain injuries. Due to the increased survival of very premature infants, the incidence of cerebral palsy may be increasing. While premature infants and term infants who have suffered neonatal hypoxic-ischaemic (HI) injury represent only a minority of the total cerebral palsy population, this group demonstrates easily identifiable clinical findings, and much of their injury is to oligodendrocytes and the cerebral white matter. While the use of stem cell therapy is promising, there are no controlled trials in humans with cerebral palsy and only a few trials in patients with other neurologic disorders. However, studies in animals with experimentally induced strokes or traumatic injuries have indicated that benefit is possible. The potential to do these transplants via injection into the vasculature rather than directly into the brain increases the likelihood of timely human studies. As a result, variables appropriate to human experiments with intravascular injection of cells, such as cell type, timing of the transplant and effect on function, need to be systematically performed in animal models with HI injury, with the hope of rapidly translating these experiments to human trials.
KW - Cerebral palsy
KW - Embryonic stem cells
KW - Marrow stromal cells
KW - Neuron
KW - Oligodendrocyte
KW - Periventricular leukomalacia
KW - Stem cells
UR - http://www.scopus.com/inward/record.url?scp=0037927556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037927556&partnerID=8YFLogxK
U2 - 10.1517/eobt.3.4.541.21207
DO - 10.1517/eobt.3.4.541.21207
M3 - Review article
C2 - 12831360
AN - SCOPUS:0037927556
SN - 1471-2598
VL - 3
SP - 541
EP - 549
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
IS - 4
ER -